Bristol Discontinues Development Of Inhibitex Nuc, Will Take $1.8 Billion Hit
This article was originally published in The Pink Sheet Daily
Executive Summary
On Aug. 1, Bristol halted Phase II study of nucleoside polymerase inhibitor BMS-986094 due to a serious case of cardiac toxicity – the pharma since has revealed that the afflicted patient died and nine total have been hospitalized with heart and kidney problems.
You may also be interested in...
Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.